New imaging agent seeks to light up hidden cancer
NCT ID NCT07052760
Summary
This early-stage study is testing a new imaging agent called 111In-ABD147 to see if it can detect metastatic cancer in patients with solid tumors. The agent is designed to attach to a protein called DLL3, which is often found on certain cancer cells. The main goals are to see if the agent can successfully highlight tumors on scans and to check its safety in up to 45 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION RESISTANT PROSTATE CANCER (CRPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.